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ABSTRACT 32 
One of the greatest challenges for the development of genetic therapies is the efficient targeted 33 
delivery of therapeutic nucleic acids. Towards this goal, we have introduced a new engineering 34 
initiative in self-assembly of biologically safe and stable nanovesicle complexes (~90-140 nm) 35 
derived from giant unilamellar vesicle (GUV) precursors and comprising plasmid DNA or 36 
siRNA and targeting peptide ligands. The biological performance of the engineered nanovesicle 37 
complexes were studied both in vitro and in vivo and compared with cationic liposome-based 38 
lipopolyplexes. Compared with cationic lipopolyplexes, nanovesicle complexes did not show 39 
advantages in transfection and cell uptake. However, nanovesicle complexes neither displayed 40 
significant cytotoxicity nor activated the complement system, which are advantageous for 41 
intravenous injection and tumour therapy. On intravenous administration into a neuroblastoma 42 
xenograft mouse model, nanovesicle complexes were found to distribute throughout the tumour 43 
interstitium, thus providing an alternative safer approach for future development of tumour-44 
specific therapeutic nucleic acid interventions. On oropharyngeal instillation, nanovesicle 45 
complexes displayed better transfection efficiency than cationic lipopolyplexes. The 46 
technological advantages of nanovesicle complexes, originating from GUVs, over traditional 47 
cationic liposome-based lipopolyplexes are discussed. 48 
 49 
 50 
 51 
 52 
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 60 
 61 
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1. Introduction 64 
 Formulations of cationic lipids that self-assemble into lipoplexes upon mixing with 65 
nucleic acids have received considerable attention. These non-viral vectors have recently become 66 
more popular with the development of small interfering RNA (siRNA)-mediated silencing and 67 
chemically-modified mRNA [1-4]. Nucleic acid therapy has great potential for the treatment of a 68 
wide range of diseases [5], however, only a small number of formulations used in vitro, make it 69 
to clinical trials as there are a number of barriers to in vivo delivery and transfection [4, 6]. 70 
Previously, we described the use of liposome-peptide receptor-targeted nanoparticles (RTNs) for 71 
both in vitro [7-11] and in vivo [12-18] nucleic acid delivery to various sites and targets in the 72 
body. These lipopolyplexes are capable of inducing nucleic acid compaction and their protection 73 
against premature degradation in biological fluids.  74 
There is always a need to improve the performance of delivery vehicles and giant 75 
unilamellar vesicles (GUVs) have some interesting properties for the development of functional 76 
nucleic acid delivery systems with tunable properties [19, 20].  Earlier, DNA-directed self-77 
assembly of GUVs has been shown, where DNA was introduced to vesicular surface by covalent 78 
conjugation [21-24]. These GUVs, also proved to be invaluable in vitro tools for the mechanistic 79 
understanding of complex and integrated biophysical and biomembrane processes [25-32]. Here, 80 
we exploit the bilayer properties of GUVs as the starting platform for self-assembly of a new 81 
generation of safe and stable lipid-peptide-nucleic acid transfectants with improved biological 82 
performance through the introduction of sugars for improved stabilization as well as targeting 83 
peptide ligands [20]. Indeed, the difference in density between the equiosmolar monosaccharidic 84 
intervesicular (external) and the disaccharidic intravesicular (internal) aqueous solutions offer 85 
vesicular stabilization and shape uniformity [33] as well as optical contrast. In addition, it is 86 
known that cationic transfectants can induce bioenergetic crisis, which dependent on cell type 87 
and mitochondrial polarization state it may initiate cell death [34]. The sugars associated with the 88 
engineered GUVs (e.g. glucose) could potentially help in re-establishing homeostasis with 89 
increased ATP synthesis, thereby overcoming cytotoxicity pertaining to cationic lipoplexes and 90 
lipopolyplexes.  91 
GUVs carrying nucleic acids may exhibit limited cell uptake and transfection efficacy 92 
due to their large size compared with conventional large unilamellar vesicles [35]. Accordingly, 93 
we have introduced GUVs as precursors for generating vesicles in the nanoscale range 94 
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(hereinafter termed “nanovesicles”). Nanovesicles were complexed with nucleic acids (DNA or 95 
siRNA) and functionalized with different targeting peptides. The latter have included: 1) ME27, 96 
which contains the Arg-Gly-Asp (RGD) motif capable of targeting integrins and particularly 97 
αvβ3, αvβ5, and α5β1 classes expressed in a wide range of tumours, 2) YGLPHKF (which is 98 
derived from peptide Y, a generic targeting peptide that works well across a range of tissues, 99 
including cells of neuronal origin) [8, 9] and closely resembles part of a targeting protein 100 
expressed by the intracellular pathogen Legionella pneumophila [36], and 3) peptide E, which 101 
has the SERSMNF motif that displays close similarity to receptor binding proteins of two 102 
intracellular pathogens, rhinovirus and Listeria monocytogenes [36]. Rhinoviruses bind the 103 
intercellular adhesion molecule-1 (ICAM-1) [37]. ICAM-1 is present in the airway epithelium 104 
and is upregulated in the inflamed epithelium as in cystic fibrosis [37, 38]. 105 
Collectively, our studies comprise biophysical characterization of targetable nanovesicle 106 
complexes as well as their improved biosafety in relevant in vitro and in vivo models compared 107 
with conventional cationic lipoplexes and lipopolyplexes.  108 
 109 
 110 
2. Experimental section 111 
 112 
2.1. Materials 113 
1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and 1,2-dioleoyl-sn-114 
glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids, Inc. 115 
(Alabaster, AL, USA). Peptide Y (K16GACYGLPHKFCG) was synthesized by ChinaPeptides 116 
Co., Ltd. (Shanghai, People’s Republic of China), peptide E (K16GACSERSMNFCG) was 117 
synthesized by Zinsser Analytics (Maidenhead, UK), peptide ME27 (K16RVRRGACRGDCLG) 118 
was synthesized by Alta Bioscience (Birmingham, UK) and the linear lysine peptide K16 was 119 
purchased from ImunnoKontact (Abingdon, UK). Dy677 control siRNA (siRNA-Dy677) was 120 
purchased from GE Healthcare (Amersham, UK).  Cy3-labelled control plasmid DNA (DNA-121 
Cy3) was purchased from Cambridge Bioscience (Cambridge, UK). The plasmid pCI-Luc 122 
consists of the luciferase gene from pGL3 (Thermo Fisher Scientific, Hemel Hempstead, UK) 123 
sub-cloned into pCI (Promega Corporation, Fitchburg, WI, USA). The plasmid pEGFP-N1 (4.7 124 
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kb) containing the gene GFP was obtained from Clontech Laboratories, Inc. (Mountain View, 125 
CA, USA). 126 
 127 
2.2. Nanovesicle formation from GUV precursors 128 
DOTMA and DOPE were dissolved in chloroform to a concentration of 10 mg/mL. Lipids 129 
were mixed at a 1:1 molar ratio. The chloroform was evaporated in a rotary evaporator (BÜCHI 130 
Labortechnik AG, Flawil, Switzerland). The lipid film was dissolved in light mineral oil (catalog 131 
number: M5310; Sigma-Aldrich, Poole, UK) to a final concentration of 1.7 mg/mL by heating up 132 
to 50ºC, sonicated for 30 min in an ultrasonic water bath (Jencons-PLS, Bedfordshire, UK) and 133 
incubated overnight at room temperature (RT). The lipid solution in mineral oil was then stored 134 
at -20ºC prior to further use. For the DOTMA/DOPE (DD) liposome preparation, the lipid film 135 
was dissolved in water followed by sonication. For the nanovesicle (DOTMA/DOPEves or DDves) 136 
preparation, we used a modified version of the water/oil (W/O) emulsion transfer method [20, 137 
26] described in detail by Hadorn et al. [23]. All solutions were prepared using Milli-Q water. 138 
Sucrose (99.5%) and glucose (99.0%) were purchased from Sigma-Aldrich (Poole, UK). The 139 
sucrose solution as well as the aqueous phase (glucose solution) was adjusted to 1000 mM 140 
(equiosmolar conditions) to avoid any osmotic pressure that would reduce vesicular stability. 141 
Consequently, the sucrose solution as well as the aqueous phase only differed in their densities.  142 
 The W/O emulsion was prepared in microtubes by adding 50 µL of the sucrose solution to 143 
400 µL of the lipid solution prepared above and vigorously grated against a microtube rack for 3 144 
min with force to aid emulsification. The intermediate phase was prepared in microtubes by 145 
adding 150 µL of the lipid solution to 300 µL of the aqueous phase and incubation at RT for 10 146 
min. To generate the nanovesicles, the emulsion was then placed on top of the intermediate 147 
phase and centrifuged for 3 min at 1500g at RT. The oil was removed by aspiration and the pellet 148 
was resuspended in the osmotically-adjusted glucose (aqueous phase) and kept at 4ºC.  149 
To prevent the nanovesicles from adhering to surfaces, microscope slides and coverslips 150 
were treated with PlusOne Repel-Silane ES (GE Healthcare, Amersham, UK) in accordance with 151 
manufacturer’s recommendation. Nanovesicle suspension (10 µL) was applied to a microscope 152 
slide and covered with a coverslip and then visualized (20x magnification) using an Olympus 153 
IX70 fluorescent microscope (Olympus Corporation, Tokyo, Japan). 154 
 155 
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2.3. Nanocomplex formation  156 
Cationic receptor-targeted nanocomplex (RTN) formulations (at a weight ratio of 1:4:1, 157 
liposome or nanovesicle: peptide: DNA or siRNA) were made by first adding the peptide to the 158 
liposome or nanovesicle DOTMA/DOPE (DOTMA/DOPE and DOTMA/DOPEves, respectively), 159 
followed by addition of the DNA or siRNA with rapid mixing and incubation for 30 min at RT to 160 
allow for complex formation. The composition and terminology of the nanocomplexes 161 
(lipopolyplexes or nanovesicle complexes) are summarized in Table 1.  162 
 163 
2.4. Size and zeta potential determinations 164 
Nanocomplex preparations were diluted with distilled water to a final volume of 1 mL at a 165 
concentration of 5 µg/mL with respect to DNA or siRNA. They were then analyzed for size and 166 
electrophoretic mobility measurements using a Malvern Nano ZS (Malvern, UK). The following 167 
specifications were used: automatic sampling time of 10 measurements/sample, refractive index 168 
of 1.330 (water) and 1.340 (5% w/v glucose), dielectric constant 78.5 (water) and 77.37 (5% w/v 169 
glucose), viscosity 0.8872 cP (water) and 1.1450 cP (5% w/v glucose), and temperature of 25ºC. 170 
DTS version 5.03, which was provided by the manufacturer, was used for data processing.  171 
 172 
2.5. Heparin dissociation assay 173 
DNA (0.2 µg) was mixed with PicoGreen reagent (1:150) (Invitrogen, Paisley, UK) at RT 174 
in Tris-EDTA buffer and the DNA/PicoGreen mixture was then formulated into nanocomplexes 175 
at a 1:4:1 weight ratio (liposome or nanovesicle: peptide: DNA) as described above. Heparin 176 
sulfate (Sigma-Aldrich, Poole, UK) was added to the PicoGreen-labelled nanocomplexes in a 177 
range of concentrations (0-2 U/mL). In each experiment, naked DNA stained with PicoGreen 178 
was used to normalize the PicoGreen signal detected from the nanocomplexes. Fluorescence was 179 
analyzed using a fluorescence plate reader, FLUOstar Optima (BMG Labtech, Aylesbury, UK). 180 
 181 
2.6. Transmission electron microscopy (TEM) 182 
For the electron microscopy investigations, the nanocomplexes were prepared as described 183 
above and were placed on a glow-discharged 300-mesh copper grid coated with a 184 
Formvar/carbon support film (Agar Scientific). After a few seconds, the grid was blotted with a 185 
filter paper. The sample was then negatively stained with 1% (w/v) uranyl acetate or 1% (w/v) 186 
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phosphotungstic acid, before blotting and then air-dried. Imaging was carried out under a Philips 187 
CM120 BioTwin Transmission Electron Microscope and operated at an accelerating voltage of 188 
120 KV. 189 
 190 
2.7 Cell culture 191 
Murine Neuro-2A and human Kelly neuroblastoma cell lines were obtained from the 192 
American Type Culture Collection (Teddington, UK). Neuro-2A cells were maintained in 193 
Dulbecco's Minimal Essential Medium (DMEM; Invitrogen, Paisley, UK) supplemented with 194 
10% (v/v) FBS, 1% (v/v) non-essential amino acids, and 1% (v/v) sodium pyruvate.  Kelly cells 195 
were cultured in RPMI1640+GlutaMAX (Invitrogen, Paisley, UK) with 10% (v/v) FBS, 25 mM 196 
HEPES and 100 U/mL Penicillin/Streptomycin. The human bronchial epithelial cells 197 
16HBE14o- (shortened to HBE) were provided by D. Gruenert, (San Francisco, CA, USA) and 198 
were cultured in Eagle’s Minimal Essential Medium with HEPES modification (Sigma, Poole, 199 
UK), 10% (v/v) FCS and 2 mM L-glutamine. All cells were maintained in a humidified 200 
atmosphere of 95% air and 5% CO2 at 37°C.  201 
 202 
2.8 DNA transfection  203 
Neuro-2A cells were seeded in 96-well plates at 2×104 cells per well 24 h prior to 204 
transfection. Following the removal of growth medium, 200 µL of complexes in OptiMEM 205 
containing 0.25 µg of plasmid DNA were added to the cells in replicates of six. Plates were 206 
centrifuged at 400g for 5 min and incubated for 4 h at 37°C, then transfection medium was 207 
replaced by the complete growth medium and incubated for a further 24 h. Luciferase expression 208 
was measured in cell lysates with a luciferase assay (Promega, Southampton, UK) in a FLUOstar 209 
OPTIMA luminometer (BMG Labtech, Aylesbury, UK). The amount of protein present in each 210 
sample was determined with the Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hemel 211 
Hempstead, UK) in a FLUOstar OPTIMA luminometer. Luciferase activity was expressed as 212 
relative light units per milligram of protein (RLU/mg). Each measurement was performed in 213 
groups of six.  214 
 The same protocol was used for transfections with eGFP plasmid DNA with the only 215 
difference being that the cells following transfection were incubated for 48 h at 37°C. They were 216 
firstly imaged (20× magnification) using an Olympus IX70 fluorescent microscope (Olympus, 217 
  
8 
 
Southend-on-Sea, UK) and then prepared for flow cytometry by detaching cells from the wells 218 
with 50 µL Trypsin-EDTA (Sigma-Aldrich, Poole, UK) and re-suspending them with 150 µL 219 
Dulbecco's phosphate-buffered saline  (DPBS; Sigma-Aldrich, Poole, UK). Cells were acquired 220 
with a BD FACSArray flow cytometer (BD Biosciences, Oxford, UK) and analyzed with FlowJo 221 
software v. 8.8.3 (Tree Star Inc., Ashland, Oregon, USA). 222 
 223 
2.9 Flow cytometry analysis  224 
After 4 h or 24 h of transfection with different nanocomplexes, the Neuro-2A cells were 225 
washed with PBS twice and then trypsinized and re-suspended in culture medium in a 96-well 226 
plate.  The uptake of the siRNA-Dy677 or DNA-Cy3 by cells in each well was analyzed using 227 
BD FACSCalibur™.  Non-transfected cells were used to set the negative control gate. Acquired 228 
data were tanalyzed using FlowJo software v. 8.8.3 (Tree Star Inc., Ashland, Oregon, USA) to 229 
determine the percentage of the Dy677-positive or Cy3-positive cells in each treatment group.   230 
 231 
2.10 In-cell Western analysis  232 
After 4, 24 and 48 h post transfection of Neuro-2A cells with different siRNA-Dy677 233 
nanocomplexes, the 96-well plate was washed twice with PBS and scanned by the Odyssey Clx 234 
infrared imaging system (LI-COR Biosciences, Cambridge, UK) and the intensity of the 700 nm 235 
fluorescent channel for each well was determined using image studio software 3.1.4. 236 
 237 
2.11 Viable cell assay  238 
Viable cell assay was assessed in 96-well plates using the CellTiter 96 Aqueous One Solution 239 
Cell Proliferation Assay (Promega, Southampton, UK). Neuro-2A cells were seeded and 240 
transfected as above. After 24 h the medium was substituted for a growth medium containing 20 241 
µL of the CellTiter 96 Aqueous One Solution reagent. Finally, after incubation for 2 h, the 242 
absorbance at 490 nm was measured on a FLUOstar Optima spectrophotometer (BMG Labtech, 243 
Aylesbury, UK). Viable cells for each formulation treatment were expressed as a percentage of 244 
the viable control cells. 245 
 246 
2.12 Complement Activation assays 247 
Details for human serum preparation, characterization and functional assessment of 248 
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complement pathways were described previously [39-41]. To measure complement activation in 249 
vitro, we determined nanocomplex-induced rise of serum complement activation products C5a 250 
and sC5b-9 using respective ELISA kits (Quidel, San Diego) according to the manufacturer’s 251 
protocol as described earlier [39-41]. Complement activation was initiated by adding the 252 
appropriate quantities of nanocomplexes (in 10 µL) to undiluted human serum (40 µL) in 253 
Eppendorf tubes in a shaking water bath at 37°C for 30 min. Reactions were terminated by 254 
addition of ice-cold sample-diluent provided in the assay kit containing 25mM EDTA. 255 
Nanocomplexes were removed by centrifugation, and complement activation products were 256 
measured in ELISA kits. Control serum incubations contained buffers that were used for 257 
liposome suspension. Zymosan was prepared as described before [41] and was used as a positive 258 
control for generating C5a and sC5b-9 at a concentration of 0.2 mg/mL.  259 
 260 
 261 
2.13 In vivo experiments 262 
Female C57Bl6 mice were purchased from Charles River (Margate, UK). All procedures 263 
were approved by UCL animal care policies and were carried out under Home Office Licenses 264 
issued in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 (UK). 265 
DOTMA/DOPE lipopolyplexes and DOTMA/DOPEves nanovesicle complexes were prepared at 266 
a weight ratio of 1:4:1 (lipid: peptide: DNA) as described previously [18] at a final plasmid DNA 267 
concentration of 0.29 mg/mL. 6-week old female C57Bl6 mice were instilled oropharyngeally 268 
with nanocomplexes in 55 µL (made in 5% glucose, v/v) containing 16 µg pCI-Luc, with 269 
untreated mice used as controls. 24 h following instillation, the mice were culled and their lungs 270 
extracted and snap frozen. Lungs were defrosted on ice, submerged in reporter gene assay lysis 271 
buffer (Roche, Basel, Switzerland), homogenized with a Precellys24 tissue homogenizer 272 
(Stretton Scientific, Stretton, Derbyshire, UK) and then centrifuged at 14,170g for 10 min at 4ºC. 273 
The supernatant was removed and centrifuged for a further 10 min at 4ºC and then used in 274 
luciferase assays. Results were expressed as relative luminescence units per milligram of protein 275 
(RLU/mg). 276 
Female NOD-SCID gamma (NSG) mice (Charles River, Margate, UK), 6 to 8 week old, 277 
were injected subcutaneously in the right posterior flank with 3 x 106 human neuroblastoma 278 
Kelly cells. After approximately 2 weeks, when tumours had reached 8–10 mm in size, 100 µL 279 
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of RTN complexes made in 5% (v/v) glucose and containing 16 µg of siRNA-Dy677 were 280 
injected into the lateral tail vein. Experiments were performed with replicates of 3 mice. 24 hours 281 
after injection, the mice were killed and tumours and organs (lung, liver, heart, kidneys and 282 
spleen) were resected and imaged using an IVIS Lumina Series III imaging system 283 
(PerkinElmer, Seer Green, UK).  The images were processed using the Living Image software 284 
(PerkinElnmer, Seer Green, UK). The tumours were then placed in 4% (w/v) paraformaldehyde 285 
(PFA) for 3 h followed by overnight incubation in 15% (w/v) sucrose/PBS and then a brief wash 286 
in 50% (v/v) ethanol and stored briefly in 70% (v/v) ethanol till ready for dissection.  287 
 288 
2.14 Preparation of frozen tissue sections 289 
Freshly dissected tissue was placed onto a pre-labelled tissue base mold. Tissue block was 290 
covered with cryo-embedding media OCT (Leica microsystems, Milton Keynes, UK). Base mold 291 
containing tissue block was snap frozen in isopentane (VWR International, Lutterworth, UK), 292 
pre-chilled in liquid nitrogen and then transferred to a cryotome cryostat, which was pre cooled 293 
to -200C. 10 µm tissue sections were prepared using the cryotome and mounted on the Superfrost 294 
Plus glass slides (Fisher Scientific UK, Loughborough, UK). The sections were dried at RT and 295 
then stored at -800C until utilized. 296 
 297 
2.15 Staining of frozen sections 298 
Tissue sections were rinsed in PBS briefly to remove any media components and fixed in 299 
pre-cooled (-200C) acetone for 10-15 min. Next, tissue sections were rinsed three times in PBS 300 
and stained with DAPI for 15 min at RT in dark. Finally, tissue sections were washed three times 301 
in PBS and sections were mounted using ProLong® Gold ant ifade mountant (Thermo 302 
Fisher Scientific, Hemel Hempstead, UK). Micrographs were taken using Leica upright  303 
fluorescence (Leica DFC310 FX) at 200x magnificat ion. 304 
 305 
2.16 Statistical analysis 306 
The data presented in this study are expressed as the mean ± standard deviation (SD) and 307 
were analyzed using a two-tailed, unpaired Student’s t-test or one-way analysis of variance and 308 
Bonferroni’s post hoc analysis, where applicable. 309 
 310 
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 311 
3. Results 312 
3.1. Biophysical characterization. The sizes and zeta potentials (Fig. 1A and Fig. S1) of 313 
nanovesicles, cationic liposomes, nanovesicle complexes and lipopolyplexes were determined 314 
first. Nanovesicles were considerably larger than their liposomal counterparts (557.0 ± 82.5 nm 315 
vs 76.1 ± 0.9 nm, respectively) consisting of two particle populations (Fig. S1) and had 316 
comparable average zeta potential values (66.9 ± 1.7 mV for nanovesicles vs 70.9 ± 2.4 mV for 317 
liposomes, respectively). These nanovesicles were capable of forming complexes with peptide 318 
and nucleic acid (DNA or siRNA) of 89.6  ± 1.3 nm, when mixed with DNA, or under 140 nm, 319 
when mixed with siRNA, respectively (Fig. 1A and Fig. S1). There was no statistical difference 320 
in the size of the nanocomplexes, however, LYDves had the least cationic surface charge among 321 
all nanocomplexes (zeta potential of 26.2 ± 0.4 mV for LYDves vs 47.7 ± 3.0 mV for LYD).  322 
Negative staining transmission electron microscopy (TEM) was used to further 323 
characterize nanovesicles (Fig. 1B) and nanovesicle complexes (LYDves; Fig. 1C). Nanovesicles 324 
and nanovesicle complexes were predominantly spherical, however, some rod-shaped objects 325 
were also present (in LYDves; Fig. 1C). The majority of the spherical entities observed by TEM 326 
for each formulation were in similar size ranges determined by dynamic light scattering (DLS). 327 
DOTMA/DOPE liposomes and LYD lipopolyplexes were also visualized (Fig. S2) and they 328 
formed some discrete spherical particles with most being aggregated in clusters. These clusters 329 
may have been generated during sample preparation and dehydration processes for TEM. 330 
The ability of nanocomplexes to package DNA efficiently and to dissociate following 331 
heparin challenge was assessed (Fig. 1D). PicoGreen-labelled DNA was formulated into cationic 332 
LYD and LYDves. Packaging was inferred from fluorescence quenching compared with free 333 
DNA as 100%.  The packaging efficiency refers to the extent of nucleic acid protection. 334 
Therefore, the higher the packaging efficiency, the better the protection of the nucleic acid cargo. 335 
Both formulations resulted in high packaging efficiency: 81% for LYD lipopolyplexes compared 336 
with 94% for LYDves nanovesicle complexes. In addition, they had a different heparin release 337 
profile. LYD achieved 50% dissociation at 0.41 U/mL heparin, whereas LYDves achieved 50% 338 
dissociation at 0.84 U/mL heparin, thus making the latter less responsive to polyanions.  339 
 340 
3.2. Cellular uptake and targeting specificity of siRNA-containing nanocomplexes. Next, we 341 
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determined cellular uptake of Dy677-labelled siRNA nanocomplexes following transfection of 342 
Neuro-2A cells in comparison with liposomes. The following complexes were used: nanovesicle 343 
complexes made from fresh nanovesicles and incorporating targeting peptides (LYRves-new and 344 
LMERves-new) or a non-targeting peptide (LK16Rves-new), nanovesicle complexes made with 345 
nanovesicles previously stored for 1 year at 4ºC and incorporating targeting peptides (LYRves-old1 346 
and LMERves-old1), lipopolyplexes with targeting peptides (LYR and LMER) or non-targeting 347 
peptide (LK16R), peptide/siRNA complexes (Y/ siRNA-Dy677 and ME27/ siRNA-Dy677), 348 
liposome/siRNA (LR) or nanovesicle/siRNA (LRves-new). Two complementary methods were 349 
used for analysis: in-cell Western analysis of the siRNA-Dy677 uptake (Fig. 2A-B) and 350 
measurement of the fluorescent intensity of the Dy677 (which reflects the uptake level of the 351 
siRNA).  The results show a time-dependent uptake of nanocomplexes. In particular, 352 
lipopolyplexes had a higher and statistically significant uptake than their respective nanovesicle 353 
complex counterparts at 4 h (LYRves uptake was 35.4% vs 53.8% for LYR, p<0.001), but this 354 
was not significant at later time points. Similar observations were made with formulations 355 
incorporating the targeting peptide ME27. The nanocomplexes that were made with nanovesicles 356 
stored for one year in the fridge had approximately a 2.5-fold increased size (215-240 nm) 357 
compared with their fresh counterparts and this might explain why the showed less uptake than 358 
freshly made counterparts. Other comparisons that were significant for all time points were those 359 
of LR (liposome/siRNA) or LRves (nanovesicle/siRNA) formulations, which displayed inferior 360 
uptake to lipopolyplexes (p<0.001). Peptide/siRNA (PR) formulations also displayed 361 
significantly less cell uptake compared with lipopolyplexes (p<0.001). Particularly, the 362 
formulations with the targeted peptides resulted in a much higher uptake than those with non-363 
targeted peptides (p<0.001 for all comparisons), however, this effect was more pronounced with 364 
the nanovesicle complexes. For example at 24 h, LYRves resulted in approximately 10-fold higher 365 
uptake than LK16Rves, which was considerably higher than the difference in uptake of LYR, 366 
which in turn was 2.6–fold higher than that of LK16R.  367 
Flow cytometry analysis (Fig. 2C), showed a similar uptake pattern to that of in-cell 368 
Western analysis at 4 h post transfection. The comparisons described above as being significant 369 
(Fig. 2A-B) were also significant in Fig. 2C. For example, the targeted formulations resulted in a 370 
much higher uptake than their non-targeted counterparts (p<0.001 for all comparisons), however 371 
again this effect was more pronounced with the nanovesicle complexes.  FACS analysis was also 372 
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performed to investigate the uptake of Cy3-labelled DNA nanocomplexes in Neuro-2A cells. 373 
The trend was the same as the one found for siRNA uptake; again there was no statistical 374 
difference between nanovesicle complexes and lipopolyplexes at 24 h and the use of targeting 375 
peptides resulted in higher uptake than non-targeting formulations (Fig. S3). However, PR and 376 
peptide/DNA (PD) complexes showed a significantly different nucleic acid uptake profile. For 377 
example at 4 h post-transfection, PD complexes (Fig. S3) achieved 22.5% uptake, which was 378 
significantly more than the 4.1% seen with the PR formulations (Fig. 2C; p<0.05). 379 
 380 
3.3. In vitro transfection efficiencies. Nanocomplexes were formulated and used for 381 
transfection of Neuro-2A and HBE cells (Fig. 3). LMED formulations were significantly better 382 
in transfection than the LMEDves (p<0.05) in Neuro-2A cells (Fig. 3A), however, this difference 383 
was not statistically significant for LYD and LYDves nanocomplexes in HBE cells (Fig. 3B). 384 
Importantly, the receptor-targeted formulations showed considerable differences in transfection 385 
efficiency compared with the non-targeted formulations. Targeted lipopolyplexes LMED 386 
(Neuro-2A cells) and LYD (HBE cells) resulted in a 3.6-fold and a 4.3-fold enhancement of 387 
transfection compared with non-targeting LK16D (p<0.001 for both Neuro-2A and HBE cells) , 388 
whereas the vesicular targeted formulations LMEDves (Neuro-2A cells) and LYDves (HBE cells) 389 
resulted in a 10.5-fold and 8.9-fold (p<0.001 for both Neuro-2A and HBE cells) increase in 390 
transfection efficiency compared with non-targeting LK16Dves, respectively.  391 
 The transfection efficiency was further evaluated with the plasmid expressing enhanced 392 
green fluorescent protein (GFP) in Neuro-2A cells 48 h after transfection. Fluorescent 393 
microscopy images of LMEDves (Fig. 3C) and LMED (Fig. 3D) nanocomplexes provided 394 
evidence of the high transfection efficiency of both formulations.  Flow cytometry analysis of 395 
GFP transfections was then performed (Fig. 4) and showed that 28.6 ± 1.9% and 33.5 ± 2.2% of 396 
cells expressed GFP following transfection with LMEDves and LMED, respectively (p<0.05).  397 
   398 
3.4. Complement activation assay and cell viability. We challenged undiluted human 399 
serum with LYD and LYDves formulations and measured the two pathway-independent soluble 400 
end-point complement activation products C5a and sC5b-9, respectively [39, 42]. The 401 
complement system is a key effector of both innate and cognate immunity recognizing danger 402 
signals through pattern recognition [43]. C5a is an anaphylatoxin and chemoattractic agent, 403 
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whereas soluble sC5b-9 is a measure of whole complement activation. The results in Fig. 5A 404 
show that neither formulations elevated sC5b-9 levels above the background compared on the 405 
basis of equivalent surface area. On the other hand, both formulations caused very small 406 
increases of serum C5a levels (Fig. 5B). For comparison zymosan treatment induced massive 407 
rises of C5a and sC5b-9 levels above background (201.3 ± 10.1 ng/mL C5a and 31.7 ± 1.6 408 
µg/mL sC5b-9, respectively). On the basis of our findings, our formulations were poor activators 409 
of the complement system and could be used for intravenous applications. Indeed, the extent of 410 
complement activation by these preparations was considerably lower than PEGylated regulatory 411 
approved liposomes (Doxil) on equivalent surface area (46 cm2) basis (8560 ± 108.1 ng/mL 412 
sC5b-9) [44]. 413 
The cell viability assessment showed no particular differences between nanocomplexes, 414 
which included lipopolyplexes and nanovesicle complexes (Fig. 5C). However, the cationic 415 
liposomes DOTMA/DOPE (from either a fresh or an older batch) were significantly more 416 
cytotoxic (65% viable cells) compared with untreated controls (p<0.001 for both batches). On 417 
the contrary, all the batches of the nanovesicles DOTMA/DOPEves did not induce any apparent 418 
cytotoxicity.  419 
 420 
3.5. In vivo lung delivery and tumour distribution. We further determined whether the in vitro 421 
results translate to in vivo performance. Firstly, LED (size: 95.3 ± 1.4 nm; ζ potential 54.5 ± 1.3 422 
mV) and LEDves (size: 96.3 ± 0.5 nm; ζ potential 43.5 ± 0.6 mV) nanocomplexes were delivered 423 
to the airways of murine lungs (Fig. 6). 24 h after administration, luciferase assay was performed 424 
on lung extracts. The mean luciferase expression from LEDves was higher than that of LED (6160 425 
RLU/mg protein for LEDves vs 4596 RLU/mg protein for LED), but this was not statistically 426 
significant. 427 
Finally, we investigated whether LMERves nanocomplexes can be delivered to tumours 428 
following systemic administration in xenograft mouse models of neuroblastoma. 24 h after 429 
intravenous administration, the organs and the tumours were removed and imaged using the IVIS 430 
III system for siRNA-Dy677 distribution. The LMERves nanocomplexes showed high retention in 431 
tumours (17.5% of the initial injected dose; the radiant efficiency of the initial dose was 432 
measured at 1.9 x 1010 photons s−1 cm−2 steradian−1 per µW cm−2), while leaving other normal 433 
tissues with extremely low (heart, liver, kidneys and spleen) or moderate uptake (lung; 5.2% of 434 
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the initial injected dose) (Fig. 7A-B).  The fluorescent radiant efficiency was 3.39-fold higher in 435 
tumours than in the lungs (Fig. S4, p<0.01). Immunostaining of the tumours (Fig. 7C-H) 436 
revealed that the siRNA-Dy677 was strongly present throughout the tumour mass and the 437 
staining was very intense in mice injected with targeted LMERves, whereas the intracellular 438 
fluorescence signals were not detected in the tumour tissues collected from control untreated 439 
mice. 440 
 441 
 442 
4. Discussion 443 
In this study, we replaced the liposomal component of lipopolyplexes, which was derived 444 
through sonication of multi-lamellar vesicles [8, 15-18, 45], with GUVs as initial templates for 445 
vector assembly (nanovesicles and nanovesicle complexes). Following further processing, these 446 
preparations were characterized and compared with sonicated liposomes. These modifications 447 
resulted in formation of large unilamellar vesicles, with the majority being less than 1 µm. The 448 
engineered vesicles comprise of a bilayer that isolates the aqueous lumen of the intermediate 449 
vesicles loaded with sucrose from the external hosting glucose solution [19, 46, 47]. When 450 
complexed with peptide ligands and nucleic acids, we were able to produce nanovesicle 451 
complexes that were less than 140 nm. The electrostatic forces involved between nanovesicles, 452 
peptides and nucleic acids most likely play a role in compaction processes and, hence, the 453 
observed reduction in size of the nanovesicle complexes compared with native nanovesicles. 454 
Indeed, the size of the nanocomplexes should preferentially be less than 200 nm to allow for 455 
efficient internalization through different endocytic processes as well as for tumour targeting 456 
[48]. 457 
While extracellular stability is an essential requirement for formulation of an efficient 458 
nucleic acid delivery system, effective transfection is also influenced by the extent of cargo 459 
release intracellularly. For instance, cationic lipopolyplexes may interact favourably with actin 460 
during internalization causing destabilization and partial release of nucleic acids directly into the 461 
cytoplasm [49, 50]. To compare particle stability and nucleic acid dissociation, nanocomplexes 462 
were incubated with heparin, which mimics actin [9, 49]. Both types of nanocomplexes achieved 463 
approximately 65% maximum release at a heparin concentration of 2 U/mL, thus suggesting 464 
their suitability for nucleic acid delivery and release.  465 
  
16 
 
Next we compared cell uptake of the engineered formulations. The higher positive charge of 466 
the lipopolyplexes compared with nanovesicles could explain the differences in cell uptake, 467 
either through better plasma membrane destabilization (causing direct nucleic acid release into 468 
the cytoplasm) and/or improved interaction with anionic components of cell surface 469 
proteoglycans [51]. Furthermore, it has been shown that shape is an important factor in cellular 470 
uptake and that rods may enter cells more readily than spheres under static conditions and 471 
particularly from a side-on mode of contact with plasma membrane [52, 53]. Indeed, nanovesicle 472 
particles were mostly spherical in shape, whereas lipopolyplexes contained a high number of 473 
rods and torroids [9, 16, 45, 54] as well as particle clusters, which could explain their higher 474 
uptake. Our results further showed that the nanocomplexes that were made with nanovesicles 475 
after prolonged storage had larger size and reduced cell uptake. It is likely that fusion processes 476 
may have caused vesicular destabilization and partial release of complexed nucleic acids prior to 477 
cell incubation. 478 
 The initial barriers to transfection are cell binding and uptake [54, 55]. Differences in 479 
efficiencies of these two processes could potentially explain the different transfection 480 
efficiencies of the nanocomplexes. LPD complexes had similar biophysical characteristics with 481 
LPDves, but displayed improved cellular uptake and this may explain the differences in their 482 
transfection efficiencies, providing that cell viability is not compromised. Our results show that 483 
plasmid DNA in LPDves nanovesicle complexes is more tightly packaged (94%) than in LPD 484 
lipopolyplexes (81%; p<0.001), however, DNA was more easily released from LPD 485 
lipopolyplexes than from LPDves nanovesicle complexes. Thus LPD having a greater cell uptake, 486 
while resulting in better DNA release within the cell, achieves the greater transfection 487 
efficiencies observed. The targeted formulations were more efficient than their non-targeting 488 
counterparts due to the presence of the targeting peptide, which resulted in a higher uptake in the 489 
cells as corroborated in Fig. 2.   490 
Although nanovesicle complexes did not show advantages in transfection and cell uptake 491 
compared with lipopolyplexes, they were considerably less cytotoxic than their liposomal 492 
counterparts. This is most likely due to their lesser cationic charge. In addition, cells may use the 493 
glucose that was present in the nanovesicle complexes (e.g., DOTMA/DOPEves) to maintain 494 
oxidative phosphorylation and ATP synthesis. It is well documented [56, 57] that cationic 495 
liposomes are cytotoxic and this could explain the reduced cell viability observed in our assay 496 
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for DOTMA/DOPE. The LPD lipopolyplexes were also found to be significantly less cytotoxic 497 
than the cationic DOTMA/DOPE liposome, which implies that DNA or siRNA may have 498 
sequestered the cationic lipid reducing its damaging effect on cells. 499 
Our in vivo studies further showed the suitability of LEDves in nucleic acid delivery. For 500 
instance, following oropharyngeal administration nanovesicle complexes were more effective in 501 
nucleic acid delivery and transfection than lipopolyplexes (LED). This observation contrasted the 502 
in vitro findings where the lipopolyplexes showed superiority. We have previously shown that 503 
nanocomplexes target mainly the airway epithelia [18], thus a plausible explanation for these 504 
differences may arise from a relatively higher destabilization of LED at the apical surface of the 505 
lung cells compared with the sugar-containing LEDves. As for tumour targeting, we used a near-506 
infrared fluorescent probe, Dy677, which results in low autofluorescence and scattering of light 507 
and enables good tissue penetration of light, which is ideal for in vivo imaging [58]. Our 508 
nanocomplexes, following intravenous administration, were mainly localized to tumours and 509 
showed less deposition to the lungs. Others have also shown that at 24 h following intravenous 510 
administration, cationic nanoparticles coupled to αvβ3 ligands were mainly expressing luciferase 511 
in tumours with minimal activity detected in the lung and heart and none in other organs [59]. 512 
This distribution pattern is very important as the nanocomplexes were able to largely avoid the 513 
reticuloendothelial system (RES), which is the major clearance mechanism of nanoparticles from 514 
the circulation [60]. This might be attributed to the targeting peptide utilized here and to the 515 
enhanced permeation and retention effect (EPR) and the leakiness of the tumour neovasculature 516 
in our in vivo model [61]. Another contributing factor may be poor complement opsonization of 517 
the engineered nanocomplexes and hence their poor recognition by macrophages of the RES, 518 
thereby allowing more nanoparticles to reach tumours. These results collectively indicate that the 519 
targeted nanovesicle complexes could efficiently deliver siRNA to the tumour tissue, and thus 520 
might have potential applications in therapeutic oncology. Finally, considering the high level of 521 
nanovesicle complex accumulation in tumour interstitium, their poor complement activating 522 
nature is clinically advantageous. Indeed, intratumoural complement activation has been 523 
suggested to accelerate tumour growth [62, 63]. 524 
  525 
 526 
5. Conclusion 527 
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 Giant liposomes have been used for biophysical investigations, namely the interaction of 528 
cytoskeleton proteins with membranes, the dynamic structures of biomembranes and the change 529 
of liposomal shapes [64-66]. These vesicles have the advantage over traditional smaller 530 
liposomal preparations of being easier to prepare in small quantities and by high throughput 531 
procedures [19, 23, 26, 47, 67, 68]. Here, we initially modified the procedure of making GUVs 532 
that resulted in nanovesicles of less than 1 µm in size and then for the first time, we reported the 533 
development of nanovesicle complexes using these nanovesicles (derived from GUV 534 
precursors). These engineered vesicles exhibited good transfection efficiency, however, unlike 535 
conventional cationic lipoplexes, nanovesicles and nanovesicle complexes neither exhibited 536 
considerable cytotoxicity nor activated the complement system. These observations are of 537 
importance, since nanovesicle complexes were able to deliver nucleic acids to both lung and 538 
tumour tissues in vivo. Nanovesicle complexes therefore represent a promising tool for 539 
improving our arsenal of safer non-viral vectors for site-specific delivery of therapeutic nucleic 540 
acids. 541 
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 746 
 747 
Name Components 
LYD (lipopolyplex) DOTMA/DOPE/Peptide Y/DNA 
LED (lipopolyplex) DOTMA/DOPE/Peptide E/DNA 
LMED (lipopolyplex) DOTMA/DOPE/Peptide ME27/DNA 
LK16D (lipopolyplex) DOTMA/DOPE/Peptide K16/DNA 
LYDves (nanovesicle complex) DOTMA/DOPE nanovesicle/Peptide Y/DNA 
LEDves (nanovesicle complex) DOTMA/DOPE nanovesicle/Peptide E/DNA 
LMEDves (nanovesicle complex) DOTMA/DOPE nanovesicle/Peptide 
ME27/DNA 
LK16Dves (nanovesicle complex) DOTMA/DOPE nanovesicle/Peptide 
K16/DNA 
LYR (lipopolyplex) DOTMA/DOPE/Peptide Y/siRNA 
LMER (lipopolyplex) DOTMA/DOPE/Peptide ME27/siRNA 
LYRves (nanovesicle complex) DOTMA/DOPE nanovesicle/Peptide Y/siRNA 
LMERves (nanovesicle complex) DOTMA/DOPE nanovesicle/Peptide 
ME27/siRNA 
 748 
Table 1. Terminology of nanocomplexes (lipopolyplexes or nanovesicle complexes). 749 
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FIGURE LEGENDS 763 
Fig. 1. Biophysical characteristics of nanovesicles, liposomes, nanovesicle complexes and 764 
lipopolyplexes (A) Size and surface charge measurements of cationic liposomes, nanovesicles, 765 
nanovesicle complexes and lipopolyplexes. Particle size was measured by dynamic light 766 
scattering. DD=DOTMA/DOPE, LYD=DOTMA/DOPE/Peptide Y/DNA, LYR= 767 
DOTMA/DOPE/Peptide Y/siRNA, DDves= DOTMA/DOPE nanovesicles, LYDves= 768 
DOTMA/DOPE nanovesicle/Peptide Y/DNA and LYRves= DOTMA/DOPE nanovesicle/Peptide 769 
Y/siRNA. (B) Negative staining TEM with 1% (w/v) uranyl acetate was used to visualize 770 
DOTMA/DOPE nanovesicles. Scale Bar= 2 µm. (C) Negative staining TEM with 1% (w/v) 771 
uranyl acetate was used to visualize LYDves nanovesicle complexes.Scale Bar= 500 nm. (D) The 772 
dissociation properties of nanocomplexes LYD and LYDves were investigated. PicoGreen 773 
fluorescence of complexes, after incubation with heparin (0-2 U/mL), was expressed as a 774 
percentage of relative fluorescence units (RFU) relative to free DNA. All experiments were 775 
repeated at least 3 times. 776 
 777 
Fig. 2. In-cell Western and flow cytometry analysis of the siRNA-Dy677 uptake of different 778 
nanocomplexes. Neuro-2A cells were transfected with different nanocomplexes and 4 h (A) or 779 
24 h (B) later the plates were scanned for in-cell Western analysis. The plates are shown in the 780 
left panel. The graphs (right panel) show the relative fluorescence units (RFU) of each 781 
formulation to that of the naked siRNA, which is set at 1. A1-A6= LYRves-new, A7-A12= LYR, 782 
B1-B6= LMERves-new, B7-B12= LMER, C1-C6= LYRves-old1, C7-C12= LMERves-old1, D1-D6= 783 
LK16R, D7-D12= LK16Rves-new, E1-E6= LR, E7-E12= LRves-new, F1-F6= DOTMA/DOPEves-new, 784 
F7-F12= DOTMA/DOPE, G1-G6= peptide Y/siRNA-Dy677, G7-G12= peptide ME27/siRNA-785 
Dy677, H1-H6=siRNA-Dy677, H7-H12= control untransfected cells. Ves-old1 refers to 786 
nanovesicles made one year earlier and stored at 4ºC and ves-new refers to freshly made 787 
nanovesicles. (C) The uptake of siRNA–containing nanocomplexes following transfection of 788 
Neuro-2A cells was measured 4 h post-transfection by flow cytometry. In all the graphs each 789 
column represents the mean ± SD from six wells. Asterisks indicate comparison of 790 
specific formulations with statistical significance (***, p<0.001). 791 
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 792 
Fig. 3. In vitro transfections of nanovesicle complexes and lipopolyplexes. (A) Nanocomplexes 793 
LMEDves and LMED (with targeting peptide ME27) and LK16Dves and LK16D (with non-794 
targeting peptide K16) were used in luciferase transfections in Neuro-2A cells (B) 795 
Nanocomplexes LYDves and LYD (with targeting peptide Y) and LK16Dves and LK16D (with 796 
non-targeting peptide K16) were used in luciferase transfections in HBE cells. The cells were 797 
assessed for luciferase expression 24 h later. Each column represents the mean ± SD from six 798 
wells, and the experiment was repeated 3 times. Asterisks indicate comparison of 799 
specific formulations with statistical significance (*, p<0.05; ***, p<0.001). (B) (C-D) GFP 800 
transfection efficiency of the LMEDves and the LMED nanocomplexes. Two formulations, 801 
LMEDves nanovesicle complexes (C) and LMED lipopolyplexes (D) were used to transfect 802 
Neuro-2A cells. GFP expression was observed by epifluorescence microscopy 48 h later 803 
(representative cells are shown in phase-contrast on the left and transfected cells appear green on 804 
the right images; Scale Bar = 100 µm). Peptide ME27 was used for all formulations.  805 
 806 
Fig. 4. Flow cytometry analysis of GFP expression in Neuro-2A cells.  The intensity of GFP 807 
expression was evaluated at 48 h following transfection. (A) Control untransfected cells. (B) 808 
Cells transfected with LMEDves nanovesicle complexes. (C) Cells transfected with LMED 809 
lipopolyplexes. FL1= fluorescence intensity, SSC= side scatter. Each experiment was performed 810 
in triplicate wells. 811 
 812 
Fig. 5. Complement activation assays and cell viability show a lack of cytotoxicity. (A) 813 
Quantification of complement activation product of sC5b-9 in human serum after incubation of 814 
different concentration of nanocomplexes. Blank (PBS) and positive control (200 µg/mL 815 
Zymosan, sC5b-9: 31678 ng/mL serum) were tested during the experiment, as were glucose 816 
(used in LYDves) and water (used in LYD). (B) Quantification of complement activation product 817 
of C5a in human serum after incubation of different concentration of nanocomplexes. Blank 818 
(PBS) and positive control (200 µg/mL Zymosan, C5a: 201 ng/mL serum) were tested during the 819 
experiment, as were glucose (used in LYDves) and water (used in LYD). Asterisks indicate 820 
comparisons of specific formulations with statistical significance (*, p<0.05; **, p<0.01; ***, 821 
p<0.001). (C) Viability of Neuro-2A cells following transfection for 24 h with different 822 
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nanocomplexes. Viability values were normalized to the untransfected control cells. All 823 
transfections were performed in groups of six. Asterisks indicate comparisons of 824 
specific formulations to the control untransfected cells with statistical significance (***, 825 
p<0.001). DD=DOTMA/DOPE, LYDold=DOTMA/DOPE liposome one year old/peptide 826 
Y/DNA, LYDnew=DOTMA/DOPE fresh liposome/peptide Y/DNA, LYDves-old1= DOTMA/DOPE 827 
nanovesicles 1 year old/peptide Y/DNA, LYDves-old2= DOTMA/DOPE nanovesicles 6 months 828 
old/peptide Y/DNA, LYDves-new= DOTMA/DOPE fresh nanovesicle/peptide Y/DNA, LDves-829 
old1=DOTMA/DOPE nanovesicles 1 year old/DNA, LDves-new=DOTMA/DOPE fresh 830 
nanovesicle/DNA, PD=peptide Y/DNA, LYRves=DOTMA/DOPE fresh nanovesicle/peptide 831 
Y/siRNA. 832 
 833 
Fig. 6. Transgene expression following in vivo transfections of mice lungs. Luciferase activity in 834 
mice lungs was detected 24 h following oropharyngeal instillation of LEDves (nanovesicle 835 
complexes) or LED lipopolyplexes. Values are background subtracted and the bar represents 836 
mean RLU/mg. 837 
 838 
Fig. 7. Tumour uptake of formulations following intravenous administration. 24 h later the mice 839 
were culled (n=3 per group) and tumours and organs were extracted and imaged for 840 
fluorescence. (A) organs (heart, lung, liver, kidneys, spleen) and tumour of a mouse that received 841 
LMERves (DOTMA/DOPE nanovesicle/peptide ME27/siRNA-Dy677) nanovesicle complexes 842 
and (B) mice tumours: control tumour (mouse was not injected) and tumour from a mouse that 843 
received LMERves nanovesicle complexes. The fluorescence signal was also investigated in 844 
histological sections of tumours of control mice (C-E) or from mice following tail-vein injections 845 
of LMERves nanovesicle complexes (F-H). The tumours were removed 24 h after the injection 846 
and the fluorescence recorded. The cell nuclei were stained with DAPI (blue) and the siRNA-847 
Dy677 in red. (C, F) DAPI staining, (D, G) siRNA-Dy677 and (E, H) merged images. Scale Bar 848 
= 50 µm. 849 
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 864 
 865 
The efficient targeted delivery of nucleic acids in vivo provides some of the greatest challenges 866 
to the development of genetic therapies. Giant unilamellar lipid vesicles (GUVs) have been used 867 
mainly as cell and tissue mimics and are instrumental in studying lipid bilayers and interactions. 868 
Here, the GUVs have been modified into smaller nanovesicles. We have then developed novel 869 
nanovesicle complexes comprising self-assembling mixtures of the nanovesicles, plasmid DNA 870 
or siRNA, and targeting peptide ligands. Their biophysical properties were studied and their 871 
transfection efficiency was investigated. They transfected cells efficiently without any associated 872 
cytotoxicity and with targeting specificity, and in vivo they resulted in very high and tumour-873 
specific uptake and in addition, efficiently transfected the lung. The peptide-targeted nanovesicle 874 
complexes allow for the specific targeted enhancement of nucleic acid delivery with improved 875 
biosafety over liposomal formulations and represent a promising tool to improve our arsenal of 876 
safe, non-viral vectors to deliver therapeutic cargos in a variety of disorders. 877 
 878 
 879 
